Purinergic Signalling and Inflammation-Related Diseases

Guest Editors:

**Dr. Tobias Engel**
Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
tengel@rcsi.ie

**Dr. Eva María Jiménez-Mateos**
Trinity College Dublin, Dublin, Ireland
jimeneze@tcd.ie

**Prof. Dr. Miguel Diaz-Hernandez**
Department of Biochemistry and Molecular Biology, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
mdiazher@ucm.es

Deadline for manuscript submissions:
closed (15 November 2021)

**Message from the Guest Editors**

Compelling evidence accumulated over the past number of decades has demonstrated purinergic signalling to mediate a broad range of cellular functions in health and disease. Among these, inflammation has attracted the most attention as one of the main pathways by which purinergic signalling contributes to diseases. Much progress has been made in dissecting purinergic signalling cascades, and, most importantly, the use of highly specific drugs targeting different components of the purinergic system has provided compelling evidence for a causal role of purinergic signalling in almost every human pathological condition ranging from cancer, to bone diseases, to diabetes, and to diseases of the brain.

This present Special Issue will provide a broad overview of how purinergic signalling regulates inflammatory pathways and the contribution of purinergic signalling to acute and chronic diseases.